Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309823 | 0.93 | F10 (0.61) | F10KLKB1 | |
| SCHEMBL12134481 | 0.91 | F10 (0.55) | F10KLKB1KDM4EL3MBTL1RXFP1 | |
| SCHEMBL10181420 | 0.84 | F10 (0.58) | F10KLKB1KDM4EL3MBTL1 | |
| SCHEMBL13038381 | 0.83 | F10 (0.68) | F10KLKB1 | |
| SCHEMBL14310044 | 0.83 | F10 (0.63) | F10 | |
| SCHEMBL10178609 | 0.81 | F10 (0.59) | F10KDM4ERXFP1 | |
| SCHEMBL12134517 | 0.79 | F10 (0.47) | F10KLKB1RXFP1 | |
| SCHEMBL13038375 | 0.79 | F10 (0.72) | F10KLKB1 | |
| SCHEMBL13313603 | 0.79 | F10 (0.63) | F10KDM4EL3MBTL1 | |
| SCHEMBL14309817 | 0.78 | F10 (0.64) | F10KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885KLKB1 192/4885KDM4E 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.